Table 4.
The average PGI of the 1-(1,3-dioxoisoindolin-2-yl)-3-aryl urea analogs (7a–f) and imatinib at 10 µM.
| Panels | 7a | 7b | 7c | 7e | 7f | Imatinib * | Gefitinib * | Thalidomide * |
|---|---|---|---|---|---|---|---|---|
| Leukemia | 1.76 | 2.72 | 1.82 | −2.6 | 1.27 | 9 | 79.68 | 15.28 |
| Non-small cell lung cancer | −2.94 | 0.01 | 2.07 | −0.7 | −3.85 | 15.68 | 63.97 | 0.06 |
| Colon cancer | −3.05 | −4.5 | −1.39 | −1.3 | −6.43 | 5.34 | 52.19 | −0.27 |
| CNS cancer | 2.36 | 1.74 | 2.02 | 2.41 | −0.74 | 5.8 | 46.13 | −4.95 |
| Melanoma | 3.38 | 4.93 | 5.03 | 2.26 | 1.76 | −0.87 | 44.99 | −0.39 |
| Ovarian cancer | −3.08 | −4.38 | −2.23 | −1.99 | −3.38 | −7.16 | 60.93 | 1.90 |
| Renal cancer | 2.74 | 0.45 | 0.50 | −2.69 | −3.733 | 3.25 | 77.89 | −2.37 |
| Prostate cancer | −2.46 | −3.40 | −1.41 | −1.19 | −4.59 | 12.5 | 59.60 | −8.60 |
| Breast cancer | 2.06 | −0.99 | 2.25 | 0.07 | −2.35 | 12.15 | 52.88 | −2.04 |
The best outcome is indicated by bold font; * The anticancer data of gefitinib and thalidomide with NSC Codes 759854 and 66847, respectively, were retrieved from official website of NCI, USA [44].